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Background: Effective therapies for transitional cell carcinoma (TCC) are limited, with objective response rates to
most chemotherapeutic regimens below 20%. The purpose of this study was to investigate the biologic activity of
combined toceranib phosphate and vinblastine chemotherapy for treatment of TCC. A secondary objective was to
compare the utility of Computed Tomography (CT) and abdominal ultrasound (AUS) in tumor response assessments.
Results: Dogs with TCC received vinblastine at 1.6 mg/m2 every 2 weeks and toceranib at 2.5–2.75
mg/kg on Monday/Wednesday/Friday. Tumor monitoring was achieved through CT and AUS. Five patients
completed the 16-week study. Based on AUS assessments, 3 dogs experienced biologic response to therapy
including partial responses (PR, n = 2) and stable disease (SD, n = 1). Based on CT, 5 dogs experienced a biologic
response (n = 2 PR, n = 3 SD). Both imaging modalities (ultrasound and CT) were found to provide repeatable
measurements between operators, however agreement between operator measurements was greater when CT
images were used to assess tumor size.
Conclusions: The combination of toceranib and vinblastine did not result in improved response rates. While
agreement in tumor volume assessments between both AUS and CT were excellent between operators, this
did not extend to assessment of tumor response. The higher rate of concordance between operators when
assessing response to treatment with CT suggests that CT should be considered for future clinical trials involving
canine bladder TCC to improve the accuracy and repeatability of tumor measurement. The data suggest that
response to therapy as assessed by AUS or CT do not predict duration of clinical response.
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Transitional cell carcinoma (TCC) of the urinary bladder is
the most common cancer of the canine bladder, and ac-
counts for 1–2% of all cancers diagnosed in dogs [1–4]. Evi-
dence suggests that certain breeds are at higher risk for
developing this disease including the Scottish Terrier, West
Highland White Terrier, Beagles, and Shetland Sheep Dogs
[5, 6]. Other reported risk factors for the development of
TCC in dogs include female sex, obesity and exposure to
herbicides [5, 7, 8]. TCC is a frustrating disease for both pet* Correspondence: london.20@osu.edu
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These tumors are often not amenable to surgical excision as
they typically involve the trigone of the bladder and/or occur
multifocally throughout the bladder secondary to intravesicle
seeding. When surgical removal can be performed it is usu-
ally palliative, as local recurrence and distant tumor relapse
rates are high with median survival times of only 3–
10 months [6, 9, 10]. Aggressive surgical techniques, such as
bladder replacement, have been attempted with very limited
success. Cystectomy with ureterocolonic anastomosis is as-
sociated with severe complications including metabolic acid-
osis, uremia, pyelonephritis and resulting in survival times of
less than 5 months [11]. Urethral stenting in dogs with TCC
affecting the urethra/trigone can temporarily relieve tumorle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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and incontinence are significant complications and in
many cases, survival times post stenting are less than
3 months [12–14]. Transurethral resection in 6 dogs re-
sulted in urethral perforation in 2 cases and tumor seed-
ing in another 2; furthermore, this procedure cannot be
performed in female dogs due to the high risk of fatal
complications [15].
Available medical therapies for canine TCC are simi-
larly disappointing with respect to outcome. The COX1/
COX2 inhibitor piroxicam has been used for over
20 years to treat canine TCC. While clinical symptoms
often improve following piroxicam administration, the
objective response rate and survival time are both low
(18% and 6 months, respectively) [16, 17]. Several differ-
ent chemotherapy agents have been used to treat canine
TCC including carboplatin, cisplatin, doxorubicin, cyclo-
phosphamide and intravesicle thiotepa. None of these
drugs result in objective response rates greater than 10–
15% [3, 4]. Piroxicam has been co-administered with car-
boplatin resulting in no significant improvements in sur-
vival [18]. Moreover, while the combination of cisplatin
and piroxicam did improve the objective response rate
in affected dogs to 71%, fatal nephrotoxicity occurred in
several patients making this therapeutic combination un-
suitable [19]. Lastly, piroxicam has been combined with
the chemotherapeutic mitoxantrone resulting in an ob-
jective response rate of approximately 35% [20]. This
drug combination is often used to treat TCC although
the reported median survival time is only 291 days from
the date of diagnosis. More recently, a clinical trial dir-
ectly compared the use of carboplatin/piroxicam versus
mitoxantrone/piroxicam therapy for the treatment of ca-
nine TCC [21]. There was no difference in the objective
response rate (13 vs 8%) or progression free interval (73
vs 106 days) between the treatment groups. Vinblastine
has been used as a single agent to treat canine TCC
resulting in a 36% partial response rate, although these
were relatively short lived as the progression free sur-
vival was only 4 months, with an overall survival time of
approximately 5 months [22]. Lastly, the use of metro-
nomic chlorambucil has also showed some clinical effi-
cacy with a reported biological response rate of 68%,
although nearly all of these consisted of stable disease
[23].
Radiation therapy has also been utilized to treat TCC
in dogs, however its use has been limited by lack of dur-
able response times and the development of late compli-
cations. In a limited number of cases radiation has been
used as the sole treatment modality, with reported me-
dian survival times of 4–16 months [4, 6, 24]. Reported
outcomes in canine TCC when adjuvant radiation ther-
apy is incorporated into the treatment regimen are
inconsistent. When radiation was combined withmitoxantrone and piroxicam in one study, the reported
response rate of 22% was not significantly different com-
pared to the use of mitoxantrone and piroxicam alone
[25]. More recently, the use of image guided intensity
modulated radiation (IG/IMRT) with or without ad-
junctive chemotherapy in one study reported a median
survival time of 614 days [26]. In addition, adjuvant low-
dose palliative radiation therapy resulted in a 61% ob-
jective response rate, with 100% of dogs experiencing
clinical benefit (CR, PR, SD) within 6 weeks of radiation
therapy [27]. While in vitro evaluation of α/β ratios in
TCC suggest that the cells will respond best to larger
fraction size [28], coarsely fractionated protocols are as-
sociated with the development of late treatment related
complications (39–56%), including urinary incontinence,
cystitis, stranguria, colonic/ureteral strictures, colonic
perforation and bladder fibrosis [4, 6, 24]. Recently de-
scribed fractionated protocols report a lower incidence
of late effects, with 0–19% of patients developing late
dose-limiting side effects [27, 29].
Distension of the urinary bladder is variable over time,
making accurate monitoring of tumor size difficult. In-
accurate assessment of tumor size can lead to altering a
treatment regimen prior to true progressive disease or
long after definitive progression has occurred. Measure-
ments are typically performed with ultrasound, despite
the fact that computed tomography (CT) and magnetic
resonance imaging (MRI) are the preferred monitoring
modality in humans [30]. The veterinary literature has
previously evaluated traditional two dimensional ultra-
sound and found high variability in measurements ob-
tained between operators and between measurements
taken by a single operator when a patient had variable
bladder distention [31]. A previous study investigated
the correlation between measurements taken by two
dimensional ultrasound, three dimensional ultrasound,
and CT. The findings indicate that three-dimensional
ultrasound correlates more closely with CT. However,
the study did not evaluate the variability between mea-
surements taken by different operators with each modality
[32]. Importantly, ultrasound is not considered an accept-
able imaging method for measuring tumors in human on-
cology due to inherent intra- and inter-operator variables
as well as the inability to precisely reproduce images in
the same plane over successive assessments [33].
Toceranib phosphate (Palladia) is a multi-targeted re-
ceptor tyrosine kinase inhibitor that disrupts the func-
tion of several members of the split kinase receptor
tyrosine kinase (RTK) family including VEGFR, PDGFR,
KIT, and Flt-3, among others [34]. Toceranib demon-
strated single agent activity against a variety of tumor
types in a phase 1 study in dogs with cancer including
several carcinomas [34]. In this clinical trial, 3 of 4 dogs
with TCC of the bladder treated with toceranib alone
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ated from experimental models supports the notion that
inhibitors of VEGFR and PDGFR may synergize with
chemotherapeutics in the treatment of urothelial carcin-
omas [35, 36]. As such, the purpose of this clinical trial
was to provide a preliminary assessment of the biologic
activity of combined toceranib and vinblastine therapy in
dogs with TCC confined to the urinary bladder, to evaluate
the repeatability of AUS and CT measurements for TCC
between different operators, and to compare the utility of
AUS and CT for assessing response to therapy.
Methods
Eligibility
This clinical trial was approved by the Clinical Research
and Advising Committee at the College of Veterinary
Medicine and Institutional Animal Care and Use Com-
mittee (IACUC) at Ohio State University. Dogs were eli-
gible if they had a TCC of the urinary bladder that
measured more than 1 cm in diameter on baseline ultra-
sound without obvious evidence of urethral involvement.
Cytologic confirmation of a diagnosis from either a urine
cytospin or traumatic catheterization was required for
study entry. Prior to enrollment dogs underwent a series
of tests including complete blood count (CBC), bio-
chemistry profile, urinalysis, abdominal ultrasound, and
thoracic radiographs. Dogs with distant metastatic dis-
ease on diagnostic imaging were not eligible for enroll-
ment, however locoregional lymph node metastasis was
permitted. Additional eligibility criteria included age of
at least 1 year, ECOG performance score of 0–1, ad-
equate organ function as indicated by routine bloodwork
(e.g., liver transaminases <3x the upper limit of normal
(ULN), creatinine <1.5x ULN), and no evidence of any
serious systemic disorder (e.g., cardiac disease) consid-
ered incompatible with the study.
Drug product and concomitant medication
Toceranib phosphate was provided by Zoetis (Madison,
NJ) in 10, 15, and 50 mg size tablets. Concomitant
medications considered acceptable for use to prevent
and/or treat drug related toxicities included famotidine,
omeprazole, metronidazole, loperamide, metoclopra-
mide, ondansetron, maropitant, tramadol, carprofen,
meloxicam and/or piroxicam at the discretion of the
attending clinician.
Study design
A total of ten dogs were enrolled in this pilot study.
Dogs were administered vinblastine every 2 weeks and
toceranib on a Monday/Wednesday/Friday basis. The
dose for vinblastine was 1.6 mg/m2 given IV every
2 weeks based on a previously published study combin-
ing toceranib with vinblastine [37]. The starting dosefor toceranib was 2.75 mg/kg with dose de-escalation
down to 2.25 mg/kg permitted in the face of adverse
events. Dogs already receiving a non-steroidal anti-
inflammatory drugs (NSAIDs) and tolerating them
without any gastrointestinal side effects continued to
receive therapy, however dose frequency was reduced
by administration on either Tuesday, Thursday, Satur-
day, and Sunday or Tuesday, Thursday, Saturday only.
Further reduction or discontinuation was clinician
dependent and done according to clinical signs. All pa-
tients received omeprazole at approximately 1 mg/kg
PO q24, with the dose rounded to accommodate avail-
able capsule or tablet sizes (10 mg capsules and 20 mg
tablets). Dogs were assessed at week 1, then every
2 weeks thereafter for a total of 16 weeks. This in-
cluded physical examination, patient weight, adverse
event assessment, CBC, hemoccult, serum biochemis-
try profile and urinalysis. A UPC was evaluated as indi-
cated by proteinuria in the absence of pyuria, bacturia,
or hematuria.
An abdominal ultrasound was performed prior to
treatment then at weeks 4, 8, 12 and 16 of study. A CT
scan was performed at baseline and at weeks 8 and 16 of
study. Only measurements taken at baseline, week 8,
and week 16 were included in the statistical assessment.
General anesthesia was used during all measurements
taken at baseline, week 8, and week 16. This allowed for
the placement of a urinary catheter to ensure a stable
bladder volume at these time points. Unscheduled visits
were conducted at interim time points as needed. Dogs
were evaluated for adverse events (AEs) at every study
visit. AEs were defined and graded according to the pub-
lished VCOG-CTCAE criteria [38]. Disease progression
or signs and symptoms definitely related to disease were
not considered AEs.
Tumor measurements: ultrasound
Baseline ultrasound measurements were obtained under
anesthesia. Following placement of a urinary Foley cath-
eter, the urinary bladder was emptied and then 2 ml/kg
of sterile 0.9% saline was instilled into the urinary blad-
der. The urinary catheter was withdrawn into the prox-
imal urethra. All sonographic exams were performed
with the patient positioned in dorsal recumbency using
a 3–12 MHz microconvex transducer (Toshiba Aplio
500, Toshiba America Medical Systems, Tustin, CA
92780). The frequency and depth of imaging were deter-
mined by the size of the urinary bladder. Neither har-
monics nor image compounding were used. The greatest
cranial-caudal axis of the urinary bladder was deter-
mined by locating the neck of the urinary bladder and
finding the scan plane with the longest urinary bladder
dimension. The plane was marked on the patient’s skin
using a pen. While maintaining the transducer parallel
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tumor length was determined. The length of the tumor
was measured using the ultrasound machine calipers to
the nearest tenth of a centimeter. To measure the max-
imum tumor height and width, the transducer was ori-
ented 90° to the sagittal plane of the urinary bladder.
Maintaining the transverse plane, the tumor was imaged
and the maximum width and maximum height of the
tumor was recorded. The left and right medial iliac
lymph nodes were measured in longitudinal and trans-
verse planes. For each case, two observers independently
located the tumor within the urinary bladder and made
measurements. One observer (DMA) made images at all
24 time points. One person (WTD) was the second ob-
server on 21 time points and a third observer (EMG)
performed measurements on the remaining 3 time
points. All observers had at least 16 years of veterinary
ultrasound experience.
Tumor measurements: computerized tomography (CT)
The CT imaging was acquired following completion of
the ultrasound examination. Dogs were placed in ventral
recumbency and scout images were acquired (GE Light
Speed, Milwaukee, WI). For the actual study, 1.25 mm
helical images were acquired from the diaphragm through
the distal aspect of the urethra. Three separate series were
performed as follows: 1. Empty urinary bladder; 2. Infuse
2 ml/kg of 0.9% sterile saline into the urinary bladder; 3.
Following intravenous administration of 2 mL/kg of
iohexol 240 (Omnipaque, GE Healthcare, Princeton, NJ
08540). Transverse images were reconstructed into sagittal
and dorsal plane images.
Measurements were made on post-contrast CT im-
ages. The dorsal plane images were initially reviewed to
evaluate the position of the urinary bladder relative to
the sagittal plane (long axis) of the patient. If the urin-
ary bladder was parallel to the sagittal plane of the pa-
tient, the maximum length of the tumor was measured
using dorsal or sagittal plane images. The maximum
width of the tumor was measured using dorsal or trans-
verse plane images. The maximum height of the tumor
was measured using sagittal or transverse plane images.
Measurements were made using a DICOM viewer
(eFilm Workstation 3.2, Merge Healthcare, Chicago, IL
60654). If the sagittal plane of the urinary bladder was
not parallel to the sagittal plane of the patient, orthog-
onal multi-planar reformats of the urinary bladder were
made using the DICOM viewer using the sagittal plane
of the urinary bladder as a point of reference. Length,
width and height measurements were of the tumor
were made using the multi-planar reformatted images
to the nearest tenth of a millimeter. Two observers
(WTD, ETH) independently made measurements of
each tumor at each time point.Response assessment
Evaluations of tumor volume were made according to
the calculation V = π/6 (L*W*H) which uses the longest
diameter in three dimensions to calculate volume [39].
This formula assumes that the tumor will have a roughly
ellipsoid shape and has been used to calculate tumor
volume from ultrasound images, CT images, and MRI
images in both human and veterinary medicine. The vol-
ume calculation was applied to the measurements from
the independent tumor evaluations in each modality,
and then the percent difference between the results were
calculated for each modality. Final assessment of the
tumor volume at that time point was made using the
mean value of the 3 longest diameter measurements
obtained in each modality.
Statistical analysis
The reliability testing for repeated measures on tumor
size (volume) was performed using intra-class correlation
(ICC) for ultrasound and CT scan, respectively. The ICC
is a measurement of variation between the values given to
each subject by ultrasound or CT scan, with a value of 1
denoting perfect reliability. Averaged values were calcu-
lated across the two repeated measurements at each visit
for CT scan. These values were compared with the aver-
aged values at each visit from ultrasound using concord-
ance correlation coefficient (CCC) and Bland-Altman
plots for longitudinal repeated measurements. The CCC
measures how closely the CT scan measurements adhere
to a 45° line (i.e., a line of perfect agreement) when plotted
against the Ultrasound values, with a value of 1 denoting
perfect agreement. Each analysis required methods to ac-
count for within-subject correlations due to repeated mea-
sures on the same subject across visits. Limits of
agreement (bias ± 1.96 SD) for the Bland-Altman plot
were calculated using Bland and Altman’s formula for
repeated measures data [40] while CCC and their confi-
dence intervals were calculated using Carrasco, King,
and Chinchilli’s method for repeated measures data [41].
All measurements were included in a mixed effect model
to test the technician effect and instrument effect on the
change of tumor size across visits. A subject-specific
random intercept was used to account for within-subject
correlation due to the repeated measures. The Kenward-
Roger adjustment to the degrees of freedom was used to
control Type I error rates [42]. Tumor size values were
natural log transformed to better approximate normality
of residuals. Kappa statistics and bootstrap confidence
intervals were computed to access the agreement be-
tween observers and between instruments based on the
clinical outcome defined on change of tumor size. A
two-sided significance level of α = 0.05 was used for all
tests. All analyses were carried out in SAS version 9.4
(SAS institute, Cary, NC).
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Demographics
Ten dogs were enrolled in the study between 2011 and
2014. The median age was 11.5 (mean 11.5, range 9–14)
years with a median weight of 13.6 kg (mean 17.1, range
8.1–29.2). Of those patients, eight were female and two
were male. Five patients were mixed breed dogs, four
were statistically over-represented breeds (2 West High-
land White Terriers, 1 Shetland Sheep Dog, and 1 Scot-
tish Terrier), and 1 was a Greyhound. Two patients had
enlarged regional lymph nodes with the potential for
metastasis, though disease spread was not confirmed by
FNA due to the risk of seeding the peritoneum. The
remaining eight had disease confined within the bladder
(T2, N0, M0). Nine patients were on NSAIDs prior to
starting the trial, and all dogs continued to receive them
at a reduced dose intensity (q48 h) while on study.
Reliability and concordance of tumor assessments
Four measurements (ultrasound assessments by two inde-
pendent observers, CT measurements by two independent
observers) were taken prior to treatment and at weeks 8
and 16 of the study (Fig. 1). As patients discontinuedFig. 1 Tumor measurements as assessed by CT and Ultrasound. a CT sag 1
head to the left and tail to the right. An irregularly margined, soft tissue m
urinary bladder. The length of the mass is 2.3 cm (white arrow). b CT trans
caudal abdomen/caudal urinary bladder. An irregularly margined, soft tissu
urinary bladder. The width of the mass (solid white line) is 3.6 cm; the heigh
of the urinary bladder. A portion of the Foley catheter (oblong white structu
ultrasound image of the urinary bladder. The dog’s head is to the left and
urinary bladder. The length of the mass (white line A) is 1.8 cm. d US tra
An irregularly margined mass is within the caudal urinary bladder. The w
(dotted white line A) is 1.68 cmthe study at various time points, nine out of ten dogs
had data on the second visit, but only five dogs had
values obtained for the week 16 assessment. Using the
volumetric formula, the size of the tumor measured by
ultrasound ranged from 65.48 to 28818.01 mm3 with a
mean of 4113.96 mm3. The same tumors measured by
CT scan ranged from 68.03 to 23625.36 mm3 with a
mean of 4264.50 mm3. Repeated measures of tumor
size (volume calculations) were tested for reliability
within the respective modality (ultrasound vs. CT). Ex-
cellent reliability was achieved for both methods, while
intra-class correlation (ICC) was slightly smaller with
ultrasound (0.92, 95% CI: 0.82–0.96), compared to CT
scan (0.98, 95% CI: 0.95–0.99). The values were then
averaged across the two observers by each method at
each visit. CT scan measurements were compared to
ultrasound using overall concordance correlation coef-
ficient (CCC) across all visits and CCC at baseline visit.
Concordance between ultrasound and CT was demon-
strated at the baseline visit (CCC: 0.96, 95% CI: 0.85–0.99)
and across all visits (CCC: 0.92, 95% CI: 0.80–0.97). Con-
cordance between CT and ultrasound was also assessed
using Bland-Altman plots (Fig. 2).– Right parasagittal, post contrast enhanced CT image with the dog’s
ass surrounded by less dense fluid (urine) is within the caudodorsal
1 – Transverse, post contrast enhanced CT images made through the
e mass surrounded by less dense fluid (urine) is within the caudodorsal
t of the mass is 1.6 cm. A gas bubble is within the right dorsal aspect
re) is ventral to the gas bubble. c US long – Parasagittal (long axis)
the tail to the right. An irregularly margined mass is within the caudal
ns - Transverse (short axis) ultrasound image of the urinary bladder.
idth of the mass (white line B) is 2.61 cm; the height of the mass
Fig. 2 Bland-Altman plot of tumor volume for ultrasound versus CT. The disagreement plot shows the difference between ultrasound and CT
methods against the average of the methods values for each subject. The two extreme lines are the +2 and −2 standard deviation
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tumor size across visits did not show significant difference
between observers (p = 0.5 from test on interaction effect
of observer by visit). However, measurements from CT
scan indicated greater change in tumor size between week
0 and week 8, compared to measurements obtained by
ultrasound (Fig. 3, p = 0.028).
Response to therapy
The median duration of treatment was 108 days (arith-
metic mean 87 days, range 14–112). Response to therapy
at week 8 and week 12 was recorded based on a 30% re-
duction in tumor volume from week 0 (partial response,Fig. 3 Change of tumor size across visits measured by CT scan and
Ultrasound. Results shown are mean ± standard errors from mixed
models including fixed effects of technician, method (ultrasound vs.
CT), visit, and interactions of technician by visit, and method by visitor PR), 20% increase in size from week 0 (progressive
disease, or PD), or less than 30% reduction/less than
20% increase from week 0 (stable disease, or SD). Based
on the mean AUS volume calculations, three patients
completed the study with a biological response to treat-
ment (2 PR, 1 SD). Based on the mean CT volume
calculations, five patients completed the study with a
biological response to treatment (2 PR, 3 SD). Three
patients were withdrawn due to progressive clinical
signs, 1 withdrew due to adverse events, and 1 with-
drew due to owner non-compliance. The three patients
with progression were withdrawn at week 8, week 12,
or week 14. True progression free interval could not be
calculated due to the 16-week duration of study.
Ultrasound measurements by individual assessors re-
sulted in 3/9 or 5/9 dogs experiencing a PR at week 8,
and 2/5 or 3/5 experiencing a PR at week 16. The inter-
rater reliability was found to be Kappa = −0.24 with a
95% bootstrap confidence interval from −0.71 to 0.2. CT
scan measurements by individual assessors resulted in 5/
9 or 8/9 dogs experiencing a PR rate at week 8, and 2/5
or 3/5 experiencing a PR at week 16. The inter-rater reli-
ability was found to be Kappa = 0.43 with a 95% boot-
strap confidence interval from 0.14 to 0.84. The inter-
rater reliability on clinical outcome (defined as tumor
size reduction categorized by PR, SD, and PD) reached
moderate agreement for CT scan, but poor agreement
for ultrasound. Clinical outcomes based on averaged
values from two operators were also recorded. Mean
ultrasound assessment resulted in 4/9 dogs experiencing
PR at week 8 and 2/5 dogs experiencing PR rate at week
Table 2 Other adverse events
Other adverse events Grade Patients Total number events
Increased ALT 1 1 1
4 1 1
Increased AST 1 1 1
Increased ALP 2 1 1
Increased Creatinine 1 1 1
2 1 1
Anemia 1 5 6
Thrombocytopenia 1 1 1




Limb Pain 1 3 3
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experiencing PR at week 8 and 2/5 experiencing PR at
week 16. The Kappa statistic between ultrasound and
CT scan was calculated as 0.16 with a 95% bootstrap
confidence interval from −0.29 to 0.71, indicating slight
agreement on tumor response between ultrasound and
CT scan.
Adverse events
Initial toceranib doses were adjusted to accommodate
available tablet sizes (10, 15, and 50 mg) and later dose
adjustments were made at clinician discretion due to ad-
verse events (Table 1). The actual starting dose ranged
from 2.27 to 2.74 mg/kg, with a mean dose of 2.59 mg/
kg. Six patients received a toceranib dose reduction and
5 had a toceranib drug holiday during the study to due
to clinical toxicities. Three of those patients required
both a drug holiday and a dose reduction to remain on
toceranib. One patient required a vinblastine dose re-
duction and 2 required vinblastine dose delays due to
clinical toxicities.
The most common adverse events were gastrointes-
tinal (GI) in origin, and are documented in Table 1. All
GI adverse events were grade 1 or 2. Nine dogs devel-
oped anorexia, six developed weight loss, five developed
vomiting, two developed nausea, seven developed diar-
rhea, and five developed an increased BUN with normal
creatinine, indicating possible GI bleeding. The second
most commonly observed side effects were hematologic
changes (Table 2), including grade 1 anemia (n = 5),
grade 1 thrombocytopenia (n = 1), grade 1 or 2 neutro-
penia (n = 8), grade 3 neutropenia (n = 1), and grade 4
neutropenia (n = 1). Two patients with suspected pre-
existing renal insufficiency (either a grade 1 BUN eleva-
tion or isosthenuria at screening) worsened while on
study, developing either grade 1 or grade 2 elevations in
creatinine. Both of these patients were on NSAIDs in
addition to study medications, and it is unknown which
medication exacerbated their conditions. Three patientsTable 1 GI adverse events
GI adverse events Grade Patients Total number events
Anorexia 1 9 13
2 3 3
Weight Loss 1 6 7
Emesis 1 5 8
Nausea 1 2 2
Lethargy 1 4 5





2 3 3developed grade 1 lameness or limb weakness, presumed
to be secondary to muscle cramping, while on treatment.
Three developed grade 2 or less elevation in liver values
(ALP, AST, or ALT) during the study. One patient with a
pre-existing grade 1 ALT elevation worsened while on
study, developing a grade 4 ALT elevation. This patient
was on both NSAIDs and toceranib and it is unknown
which medication was responsible for worsening of the
baseline values.
Discussion
Canine TCC remains a challenging disease to treat both
surgically and medically, as most dogs have large invasive
tumors, and response rates to chemotherapeutics are low
(often <20%) and of short duration. Local disease resulting
in substantial impairment of quality of life is the primary
reason for euthanasia in the majority of canine TCC pa-
tients. Despite multiple efforts, there have been no
significant improvements in outcome in the treatment of
canine TCC over the past 15 years. A survival benefit is
reported in human TCC with adjuvant chemotherapy
(methotrexate, vinblastine, doxorubicin and cisplatin),
with response rates of 35–65% in the setting of metastatic
disease. However, recurrence rates are high with reported
median survival times reaching 12–15 months in people
with metastatic disease [43–45]. More recently, check-
point inhibitor therapy through the use of monoclonal
antibodies directed at PD1 have demonstrated single agent
activity in people with metastatic TCC [46].
This clinical trial combined two therapies that have
shown promise in treating canine TCC, vinblastine and
toceranib, and evaluated the utility of ultrasound and
CT for reproducibility and reliability in assessment of
tumor volume and response to therapy. The underlying
goal of this study was to provide preliminary data to
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blastine/toceranib and imaging modalities in canine
TCC. Our study found that response to therapy was not
improved by using a combination of vinblastine and
toceranib. In a previous study, single agent vinblastine
was shown to induce stable disease in 50% of patients
and partial responses in 36% of patients, with an overall
biological response (PR and SD) rate of 86% [22]. Using
this combination protocol, 30% of dogs experienced SD,
and 40 or 60% (AUS or CT, respectively) of dogs experi-
enced a PR to therapy at week 8 of the study. Therefore,
the observed clinical benefit (PR and SD) reported
herein is similar to published response rates using
single-agent vinblastine [22]. It is possible that the
current study did not demonstrate enhanced benefit of
the vinblastine/toceranib combination as it required re-
duction in vinblastine dose to 1.6 mg/m2, representing a
nearly 50% decrease from the 3 mg/m2 used for the sin-
gle agent study. In addition, given the limited power of
this study, it is possible that a larger population size
would allow detection of a clinically significant differ-
ence with vinblastine/toceranib treatment compared to
single-agent vinblastine.
Interestingly, tumor response at week 8 did not predict
the duration of response to the combination protocol.
Four patients withdrew prior to week 16 of the study (n
= 3 PD, n = 1AE). Of the three patients that withdrew for
PD, 2 had SD at the 8 week ultrasound evaluation, and
all 3 had a biologic response (2 PR, 1 SD) at the 8 week
CT. Only slight concordance was found between mean
volume measurements obtained through CT and AUS.
This indicates that the modalities are not interchange-
able. Therefore, imaging comparisons should be under-
taken using volume estimates obtained from the same
imaging modality.
The repeatability of tumor volume measurement extrap-
olated from AUS using the equation (π/6 (L*W*H)) by
different operators was excellent, however this technique
was not shown to be useful for assessment of clinical pa-
tient status. Determining the response to treatment (PR,
SD, or PD) for tumors based upon volumetric assessment
obtained through AUS was found to have an unacceptably
high variation between operators. Overall concordance in
tumor response assessment (according to the categories of
PR, SD, PR) was poor for ultrasound. Clinically significant
differences (measurements resulting in a different re-
sponse assessment) occurred 60% of the time. A total
of seven patients had a clinically significant difference
in operator measurements at least once while on trial.
Excellent inter-operator repeatability for tumor volume
measurement using volumetric assessment extrapolated
from CT with the equation (π/6 (L*W*H)). Determining
the response to treatment (PR, SD, or PD) for tumors
based upon volumetric assessment obtained through CTwas found to have improved repeatability between opera-
tors when compared to ultrasound. Overall concordance
in tumor response assessment (according to the categories
of PR, SD, PR) was found to be moderate for CT. This
resulted in clinically significant differences only 28% of
the time. A total of three patients had clinically signifi-
cant differences in their measurements at least once
while on trial.
The proposed reason for the inter-operator variations
in patient response assessment on both CT and ultra-
sound is a product of both the small size of the tumors
evaluated and the volume equation utilized. While excel-
lent concordance can be seen between volume assess-
ments overall, small changes in numerical differences
are magnified when the results are evaluated in terms of
percent change from baseline. This compounds the
existing inherent error in a volume calculation that as-
sumes an ellipsoid shape for a tumor that may be highly
irregular. The improved repeatability of response assess-
ment by different operators with CT is notable, and indi-
cates a more accurate estimate of changes in tumor
volume is possible when the longest diameter measure-
ments for length, width, and height are obtained through
CT. Alternative methods for volume calculation, including
the use of the perimeter method, may result in more
accurate and repeatable volume assessments. This may
permit improved tumor response assessment while still
remaining simple and rapid enough for use within a
standard clinical setting [32, 47].
Several inherent weaknesses in this study should be
noted. The small sample size in this pilot study limits ro-
bust interpretation of the results and increases the risk
of making a type II error. In addition, this study lacked a
prospective control group and was not randomized,
making direct comparisons difficult.
As mentioned previously, volumetric tumor assess-
ment by either modality at 8 weeks did not correlate
with duration on study, indicating that neither AUS nor
CT imaging will accurately predict the duration of re-
sponse to therapy. Based on inter-operator variability
and the lack of correlation between clinical outcome
and imaging, clinical decision-making based upon
image findings alone is not recommended. Alternative
measures of disease burden, including activating BRAF
mutations, survivin and telomerase activity have also
been evaluated in TCC [48–51].
Conclusions
The data presented in this pilot study indicate that the
combination of toceranib and vinblastine treatment in
canine TCC provide no obvious improvement in clinical
benefit (PR and SD) when compared to previously stud-
ied treatment modalities. In the present study, the most
consistent assessment of tumor response to treatment
Rippy et al. BMC Veterinary Research  (2016) 12:257 Page 9 of 10was obtained using tumor volume extrapolated from
CT. Given the variability in assessment of tumor response
between different operators and the poor correlation be-
tween measurements and clinical outcome, making clin-
ical decisions based upon imaging characteristics alone is
not recommended, however additional prospective studies
are warranted to confirm these findings.
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